So this was your response if I recall our prior discussion correctly:
> This is simply untrue.
> There's too much wrong with your link to debunk it. It's almost entirely wrong. Mostly, there is a different QALY threshold applied when drugs are used for people with life expectancy of under 24 months, and also they're using an unsourced value for QALYs.
"There's too much wrong with your link to debunk it" isn't much for me to go on to change my assessment of the story.
Moreover, I don't think any of your assertions can change the result, for several reasons:
1) The BBC article I linked to says: "NICE aims to spend less than £20,000 to £30,000 per Qaly. That is not a hard limit; it will go almost twice as high for end-of-life drugs."
You say that "there is a different QALY threshold applied when drugs are used for people with life expectancy of under 24 months."
But if life expectancy is under 24 months, the total amount NHS spends is correspondingly limited, even if the per-year threshold is higher. Even if NHS would pay 60,000 pounds per QALY for end-of-life care, with a 2-year life expectancy, you're not coming close to the $500,000 the U.S. insurance company paid.
2) My estimate is conservative to begin with. The course of treatment actually cost more than $500,000 (the lady paid hundreds of thousands of dollars during the two-year period after exceeding the lifetime limit). I also estimated British costs at half of U.S. costs. But if most of the costs in this situation were due to drugs subject to a higher QALY limit, the that would be an overly conservative assumption, since cutting-edge cancer drugs aren't half the price in the U.K. as in U.S. (while services may be).
In this particular case, probably over 500,000 pounds was spent to extend this person's life by maybe a year if that. I don't think anything you've provided suggests that NHS would have spent that much, or even the 400,000 pounds the U.S. insurance company actually spent.
I also don't understand your point about my "assumptions." I'm not assuming expensive treatment is good treatment. I'm saying expensive treatment is what people want, and U.S. insurance companies are willing to pay for it, and NHS is much less willing to pay for it. That's my point. Here in the U.S., the outrage is why the insurance company didn't pick up the tab for the other couple of hundred thousand dollars. Nobody is willing to suggest that maybe we do what the NHS would have done, and deny such expensive treatment for someone with such a bad prognosis.